HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy.

HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy.

OBJECTIVES: Antiretroviral therapy (ART) decreases HIV-1 RNA levels in semen and reduces sexual transmission from HIV-1-infected men. Our objective was to study the time course and magnitude of seminal HIV-1 RNA decay after initiation of efavirenz-based ART among 13 antiretroviral-naïve Kenyan men....

Full description

Bibliographic Details
Main Authors:	Graham, S, Holte, SE, Dragavon, J, Ramko, K, Mandaliya, K, McClelland, R, Peshu, N, Sanders, E, Krieger, J, Coombs, R
Format:	Journal article
Language:	English
Published:	2012

Similar Items

HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy.
by: Susan M Graham, et al.
Published: (2012-01-01)

Post-prostatic massage fluid/urine as an alternative to semen for studying male genitourinary HIV-1 shedding
by: Graham, S, et al.
Published: (2011)

Post-prostatic massage fluid/urine as an alternative to semen for studying male genitourinary HIV-1 shedding.
by: Graham, S, et al.
Published: (2011)

Antiretrovirals slowly become more available
Published: (2002-01-01)

A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy
by: Masese Linnet N, et al.
Published: (2011-11-01)

Semen bacterial concentrations and HIV-1 RNA shedding among HIV-1-seropositive Kenyan men.
by: Korhonen, C, et al.
Published: (2017)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
by: Gary Maartens
Published: (2020-01-01)

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz
by: Larru B, et al.
Published: (2014-05-01)

Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
by: Globahan Ajibola, et al.
Published: (2020-01-01)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
by: Vandercam Bernard, et al.
Published: (2010-05-01)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
by: Selemani Saidi Sungi, et al.
Published: (2018-10-01)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
by: Chang Huang, et al.
Published: (2023-03-01)

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.
by: Jan Vesterbacka, et al.
Published: (2013-01-01)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
by: Sanjeev Sinha, et al.
Published: (2017-12-01)

Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil
by: T. Vanni, et al.
Published: (2007-07-01)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.
by: Patience Nyakato, et al.
Published: (2020-01-01)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017)

Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer
by: Marcel A. Schneider, et al.
Published: (2021-11-01)

Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador
by: Alejandro Checa, et al.
Published: (2020-07-01)

Efavirenz in pregnancy
by: Polly Clayden, et al.
Published: (2010-11-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
by: Tarcyla Andrade Gomes, et al.
Published: (2015-10-01)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
by: Adelline Twimukye, et al.
Published: (2021-11-01)

Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy.
by: Summer L Day, et al.
Published: (2013-01-01)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
by: Dorward, J, et al.
Published: (2023)

Efavirenz-induced urolithiasis.
by: Wirth, G, et al.
Published: (2006)

Efavirenz and neuropsychiatric effects
by: Mukesh Dheda
Published: (2017-04-01)

Viremia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy
by: Dorward, J, et al.
Published: (2024)

"Slowly But Sure"
by: Aisyah Tiara Rahmah, et al.
Published: (2022-01-01)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
by: Gabriella Jomara da Silva, et al.
Published: (2023-05-01)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
by: Rebecca Zash, MD, et al.
Published: (2018-07-01)

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe
by: Sandra Shawarira-Bote, et al.
Published: (2019-08-01)

Clinical outcomes after Viremia among people receiving dolutegravir vs efavirenz-based first-line antiretroviral therapy in South Africa
by: Asare, K, et al.
Published: (2023)

Efavirenz-Induced delayed onset cerebellar ataxia and encephalopathy
by: G R K Sarma, et al.
Published: (2022-01-01)

Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study
by: Tinei Shamu, et al.
Published: (2024-02-01)

Correction: Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1.
Published: (2004-12-01)

Gaia16apd – a link between fast and slowly declining type I superluminous supernovae
by: Kangas, T, et al.
Published: (2017)

Efavirenz: History, Development and Future
by: Bárbara Costa, et al.
Published: (2022-12-01)

A comparison of historical and contemporary reproductive traits in a declining population of Glaucous-winged Gulls (Larus glaucescens)
by: Louise K. Blight, et al.
Published: (2022-12-01)

Doubts are slowly dissipating
by: Chung, Clarissa
Published: (2021)

SLOWLY DOWN THE GANGES /
by: 623246 Newby, Eric
Published: (1983)